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Summary. The most important effect of dihydroergotamine is venoconstriction, but certain metabolic effects and changes 
in vessel prostanoid activity have also been suggested. In this study endothelial cell production of 6-keto PGF1, and TxB z 
was quantitated in vitro. No evidence of altered prostanoid production was noted after incubation with dihydroergotarnine 
(exposure ranging from 5 x 10-3 to 5 x 10- v g/l). Similarly, no effect ofdihydroergotamine on the growth rates of  endothe- 
lial cells or smooth muscle cells in vitro was documented. 
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Dihydroergotamine (DHE), a dihydrogenated ergot alka- 
loid, has potential clinical usefulness in treating a variety of 
vascular diseases. Among its effects are hemodynamic alter- 
ations induced by interaction with e-adrenoreceptors. This 
effect of DHE can only partly be blocked by phentolamine, 
thus differentiating it from that of noradrenaline. The re- 
maining tension can be blocked by inhibitors of the 
prostanoid system 1-3. In this regard, fluid in which vein 
strips are immersed after administering DHE contains in- 
creased activity of a prostanoid E-like substance z. Similarly, 
increased production of prostacyclin has been reported in 
immersion fluid from DHE treated rabbit vessels 4 and in 
human veins in vitro 5. This effect on prostanoids could not 
be verified in an in vivo study on healthy volunteers 6. Thus 
the question arises: does DHE cause prostanoid release? In 
addition DHE induces metabolic changes that theoretically 
could interfere with cell metabolism and cell replication 7. 
This study was undertaken to ascertain whether DHE had 
any effect on endothelial or smooth muscle cell proliferation, 
or endothelial cell prostanoid synthesis in vitro. 
Material and methods. Endothelial and smooth muscle cell 
derivation. Endothelial cells from dog external jugular veins 
were harvested enzymatically with trypsin and collagenase as 
previously described by Ford et al. 8. A homogeneous endo- 
thelial cell culture was ascertained by morphologic study and 
factor VIII expression. 
Smooth muscle cells were derived from canine carotid arter- 
ies. They were cleaned of adventitia and endothelium, 
minced, and placed into an enzyme solution of elastase 
type III  and collagenase CLS type I. The high purity of the 
cell cultures was ascertained by morphological characteriza- 
tion, including presence of numerous myofilament bundles 
in the cytoplasm and vesicles near the membranes. For details 
of methodology see Lindblad et al. 11. 
Endothelial and smooth muscle cell growth rate determination. 
Primary endothelial cell cultures, after 7 -10  days growth, 
were trypsinized, pooled, passed and placed in serum-coated 
16-mm culture wells (Costar, Cambridge, MA, USA), at a 
density of approximately 10,000 cells/well. The medium was 
medium 199, with 20 % fetal bovine serum (FlowLab, Rock- 
ville, MD, USA), gentamicin (5 gg/ml, Schering, Kenil- 
worth, N J, USA), and a high concentration of endothelial cell 
growth factor (100 gg/ml, Seragen, Boston, MA, USA). No 
heparin was added to this medium. Dihydroergotamine me- 
sylate (DHE 45, Sandoz Inc., East Hanover, NJ, USA) was 
added to the medium, at concentrations of 5 x 10-a; 
5 x 10-4; 5 x 10-s; 5 x 10-6; and 5 x 10 -7 g/1. Medium 
without DHE served as a control. Sixteen wells were used for 
each DHE concentration studied. These DHE concentra- 
tions ranged from 1000 times higher to 10 times lower than 
the plasma concentration normally achieved in clinical set- 
tings. Addition of DHE did not affect the pH of the medium. 
The nutrient medium, with or without DHE, was changed 
every other day during the cultivation period. 
Smooth muscle cells, after primary cultivation, were 
trypsinized, pooled, washed, spun, and resuspended in medi- 
um as above. Into each 16-mm tissue culture well 8000 cells 
were plated. Different concentrations of DHE were added 
giving a final concentration of DHE ranging from 5 x 10-3 
to 5 x 10- 7 g/1. In a control group no DHE was added. Both 
endothelial and smooth muscle cell cultures were maintained 
in a 37 ~ incubator with a 100 % humidified atmosphere gas 
consisting of 5 % CO z and 95 % air. 
Initial seeding density was determined for 24 samples taken 
during plating. Plating efficiency was measured from 4 wells 
trypsinized at day 3. At the end of 7 days the remaining cells 
(12 wells) were trypsinized and counted using a Coulter ~ 
counter. 
Endothelial cell prostanoid production. The endothelial cell 
culture medium was changed on day 6, and on day 7 the 
medium incubated for 24 h with the cells was removed and 
immediately frozen for later assay ofprostanoid production. 
Prostanoid metabolites were determined after extraction of 
proteins and free fatty acids 9.6-keto PGFI~ was determined 
utilizing a radioimmunoassay kit (New England Nuclear, 
detection limit 3.8 pg). TxB z was also determined by ra- 
dioimmunoassay (New England Nuclear, detection limit 
0.5 pg). The assays have low cross-reactivity to related 
prostanoids 9. Statistical analysis was performed with the 
Wilcoxon rank sum test. Mean values _+ SEM are given. 
Results. Endothelial cell growth (table). The mean initial 
seeding density for the endothelial cells was 11,206 ___ 253/ 
welt. Plating efficiency measured at day 3 did not differ 
markedly, being 15,162 _+ 765-16,376 _+ 534. This cell den- 
sity increased approximately 15-fold by the 7th day being 
158,300 _+ 1,315 in control wells. No difference between the 
Endothelial cell and smooth muscle celt growth*, at 7 days from an initial cell density of 11,206 • 253 and 7613 + 176 cells, respectively (n = 12, 
x + SEM) 
Dihydroergotamine concentration (g/l) 
5 • 10 -3 5 • 10 -4  5 • 10 -5 5 • 10 -6 5 x 10 -~ None (control) 
Endothelial 153,530 159,370 151,745 167,594 166,370 158,300 
cells + 1120 • 860 • 1710 • 2060 + 1625 • 1315 
Smooth 9036 9051 8876 8872 8963 9017 
muscle cells • 389 • 288 • 421 • 332 • 312 • 246 
* No statistically significant differences, comparing any concentration of DHE to controls. 
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groups which were exposed to different DHE levels was seen 
(range 151,745_+ 1710-167,594 _+ 2060 cells/well). Exami- 
nation of cells by phase contrast microscopy revealed no 
changes that could be ascribed to DHE. 
Smooth muscle cell growth (table). Initial seeding density of 
smooth muscle was 7613 _+ 176 cells/well. Plating efficiency 
measured at day3 did not differ markedly being 
5865 _+ 380-5976 + 412. By day 7 after seeding, the cell 
count had increased, with control wells containing 
9017 _+ 246 cells and DHE treated wells between 8872 + 332 
and 9051 + 288 cells. Phase contrast microscopy revealed no 
changes in cell configuration. 
Endothelial cell prostanoid production. The 24-h incubated 
media had concentrations of 6-keto PGF1, of 3380 _+ 
380 pg/ml in controls, and a range of 3160 + 425-3370 _ 
510 pg/ml in DHE wells. TxB 2 levels were 5810 + 1020 pg/ 
ml in controls and ranged from 4210 + 1400 to 6960 + 
1310 pg/ml in DHE wells. No significant differences existed 
between control medium and that to which DHE had been 
added. 
Discussion. In the current study we could not verify increased 
activity of prostanoids in vitro from cultured endothelial 
cells exposed to DHE. We have reported previously on the 
effects in vivo on healthy volunteers of indomethacin pre- 
treatment before DHE administration. After pretreatment 
the same hemodynamic effects were observed as with no 
pretreatment; namely, increased venous flow velocity, re- 
duced venous cross-sectional area, and reduced resting calf 
blood flow volume 6' ~o. These results, contrary to those of 
others, suggest little importance of prostanoids in the action 
of DHE. Measured under identical conditions, other agents 
show substantial variation in the prostanoid activity. Re- 
duced release of prostanoids has been noted for acetylsali- 
cylic acid ( -  55 %) and other cyclooxygenase and throm- 
boxane inhibitors, whereas dipyridamole, a phosphodieste- 
rase inhibitor, did not alter prostanoid activity, and 
thrombin administration increased prostanoid activity ~ 1. 
In addition to the direct vascular effects of DHE, metabolic 
alterations have also been ascribed to DHE. Included among 
these are reductions in liver glucose output, inhibition of 
adrenaline-induced hyperglycemia, stimulation of lipolysis, 
inhibition of cAMP degradation, interference with phospho- 
diesterase and increased pyruvate/lactate ratio during rela- 
tive hypoxia 7' 12. Because of the potential effect of these 
changes on cell growth, we attempted to define whether there 
was any interaction between DHE and in vitro endothelial or 
smooth muscle plating efficiency and cell proliferation. Our 
data show that no such effect exists in this setting. 
* Present address: Department of Surgery, University of Lund, Maim6 
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Inhibition by tetanus and botulinum A toxin of the release of [3H]noradrenaline and [3H]GABA from rat 
brain homogenate 
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Summary. Rat brain homogenate was preloaded with [3H]noradrenaline or [3H]GABA and stimulated with high K +. 
Tetanus toxin and botulinum A neurotoxin partially prevent the evoked [3H]noradrenaline release in the same range of toxin 
concentrations starting below 10 -1~ M. In contrast, release of 7-amino butyric acid (GABA) is much more sensitive to 
tetanus than to botulinum A toxin. 
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Recently it has been claimed 1 that tetanus toxin does not 
inhibit the evoked release of [3H]noradrenaline from rat 
cerebral cortex slices. The statement contradicts our positive 
findings, obtained using two different experimental designs, 
on rat brain homogenate 2, 3. Using an improved superfusion 
system, we now show that both tetanus and, still better, 
botulinum A toxin prevent noradrenaline release. In con- 
trast, the release of GABA, which is known as an inhibitory 
neurotransmitter, is inhibited preferentially by tetanus toxin. 
Method. Rat brain cortex was cut into 0.3 x 0.3 mm prisms 
with a McIlwain chopper and suspended in Hepes (10 mM, 
pH 7.4) buffered ice-cold Krebs-Ringer solution (KRH). Af- 
ter a short trituration with an Eppendorfpipette, the suspen- 
sion (10% w/v) was passed three times by hand through a 
Potter homogenizer with a loose-fitting pestle. After 3 min 
centrifugation at 4500 x g and washing once, the sediment 
was taken up to give 2% (w/v) with respect to original 
weight. For studying noradrenaline release, this suspension 
was mixed with half its volume of KRH containing (final 
concentration) noradrenaline (1 mCi/1, 1 p-M), iproniazid 
(10 p.M) and ascorbic acid (20 p-M). All subsequent solutions 
contained iproniazid and ascorbic acid. After 15 min shak- 
